Skip to records

Therapeutics

229Aging Biotech
100 of 229 records

Rinvatercept

Source date not recordedAnalyse record ↗

Activin and myostatin ligand trap with a registered Phase 2 Duchenne muscular dystrophy study not yet recruiting.

Modality
modified activin receptor type II ligand-trap protein
Availability (US)
Phase 2 DMD study registered as Not yet recruiting; company reported program initiation in August 2026
Biomarkers
treatment-emergent adverse events; pharmacokinetics; anti-drug antibodies; body composition; motor, cardiac and pulmonary function
Hallmark targeted
stem and muscle niche, TGF-beta signaling, muscle and bone homeostasis
Kind
investigational biologic
Clinical trials
NCT07704099 — Phase 2, Not yet recruiting on August 10, 2026 update; estimated start September 14, 2026